یکشنبه 18 خرداد 1404
[Archive]
دوره 31، شماره 148 - ( 8-1402 )
جلد 31 شماره 148 صفحات 498-488 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rafiee M, Bonakchi H, Rahimi Pordanjani S, Shahrokhi S Z, Mohagheghi S, Allahbakhshian Farsani M et al . Enhancing CD34+ Cell Mobilization and Engraftment after Autologous Hematopoietic Stem Cell Transplantation via Adjustment of Granulocyte Colony-Stimulating Factor Dose and Period, a Single Center Experience. J Adv Med Biomed Res 2023; 31 (148) :488-498
URL: http://journal.zums.ac.ir/article-1-7052-fa.html
URL: http://journal.zums.ac.ir/article-1-7052-fa.html
Enhancing CD34+ Cell Mobilization and Engraftment after Autologous Hematopoietic Stem Cell Transplantation via Adjustment of Granulocyte Colony-Stimulating Factor Dose and Period, a Single Center Experience. Journal of Advances in Medical and Biomedical Research. 1402; 31 (148) :488-498
چکیده: (1630 مشاهده)
Background and Objective: Insufficient mobilization of hematopoietic stem cells and delayed engraftment are reported in autologous hematopoietic stem cell transplantation (AHSCT). The aim if this study was to identify and introduce predictive factors for mobilization and engraftment.
Materials and Methods: The participants include AHSCT candidates. Pre-apheresis CD34+ cells and CD34+ count per kilogram (CD34+ CPK) in the apheresis products were assessed by flow cytometry. There were other parameters connected to platelet and neutrophil engraftment as well as mobilization by granulocyte-stimulating growth factor (G-CSF). Univariate, multivariate, and receiver operating characteristic (ROC) analyses were used in the statistical study.
Results: The predictive value of CD34+ CPK for platelet engraftment was fair (AUC: 76.9%) with the cut-off of 3.5×106, while it was poor for neutrophil engraftment (AUC: 64.4%) with the cut-off of 3.4×106. The multiple-variate analysis demonstrated that age and CD34+ CPK were positively correlated with platelet engraftment (p-values less than 0.01 and 0.005, respectively), while CD34+ CPK and total dose of infused G-CSF (TDIG) were associated with neutrophil engraftment (p-values: 0.03). In high rates, the TDIG correlated negatively with CD34+ CPK, CD34+ cell counts in pre-apheresis peripheral blood samples, and total engraftment, indicating negative effects of high and long-term doses of G-CSF on mobilization and engraftment.
Conclusion: The management of AHSCT will be more efficient by considering the age, CD34+ CPK, and TDIG. For enhanced engraftment, adjusting the G-CSF injection days for <4 days and total dose of G-CSF on <4000 micrograms are suggested.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Clinical Medicine
دریافت: 1402/1/3 | پذیرش: 1402/4/5 | انتشار: 1402/8/7
دریافت: 1402/1/3 | پذیرش: 1402/4/5 | انتشار: 1402/8/7
فهرست منابع
1. Hübel K, Ostermann H, Glaß B, et al. Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transplant. 2019;54(1):123-9. [DOI:10.1038/s41409-018-0228-z] [PMID] [PMCID]
2. Rafiee M, Farsani M.A, Amiri V, et al. Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis. Int J Hematol 2021;114, 235-45. [DOI:10.1007/s12185-021-03154-2] [PMID]
3. Ali N, Adil SN, Shaikh MU. Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cell Transl Med. 2015;4(8):873-7. [DOI:10.5966/sctm.2015-0015] [PMID] [PMCID]
4. Grubovic R, Georgievski B, Cevreska L, Genadieva-Stavric S, Grubovic MR. Factors associated with successful mobilization and collection of peripheral blood hematopoietic stem cells in autologous and allogeneic donors. South East Europ J Immunol. 2017;2017:1-6. [DOI:10.3889/seejim.2017.20012]
5. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295-308. [DOI:10.1016/j.bbmt.2013.10.013] [PMID]
6. Kim JS. Hematopoietic stem cell mobilization: current status and future perspective. Blood Res. 2017;52(2):79-81. [DOI:10.5045/br.2017.52.2.79] [PMID] [PMCID]
7. Alexeev S, Babenko E, Estrina M, Mikhailova N, Zubarovskaya L, Afanasyev B. Factors influencing stem cell mobilization in patients with hematologic malignancies and solid tumors. Cell Ther Transplant. 2009;1(3).
8. Ratajczak MZ, Adamiak M, Plonka M, Abdel-Latif A, Ratajczak J. Mobilization of hematopoietic stem cells as a result of innate immunity-mediated sterile inflammation in the bone marrow microenvironment-the involvement of extracellular nucleotides and purinergic signaling. Leukemia. 2018;32(5):1116-23. [DOI:10.1038/s41375-018-0087-z] [PMID] [PMCID]
9. Song GY, Jung SH, Ahn SY, et al. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. BMC Cancer. 2019;19(1):59. [DOI:10.1186/s12885-019-5285-1] [PMID] [PMCID]
10. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplantat. 2006;37(8):719-24. [DOI:10.1038/sj.bmt.1705298] [PMID]
11. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;5(3):213-26. [DOI:10.1089/scd.1.1996.5.213] [PMID]
12. Bejanyan N, Brunstein CG, Cao Q, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909-22. [DOI:10.1182/bloodadvances.2017014464] [PMID] [PMCID]
13. Jantunen E, Kuittinen T, Nousiainen T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma? Bone Marrow Transplant. 2003;32(6):569-73. [DOI:10.1038/sj.bmt.1704184] [PMID]
14. Gutierrez Aguirre CH, Gomez-Almaguer D, Alvarado Navarro DM, et al. Low-dose plerixafor and granulocyte colony-stimulating factor for first-line autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma. Blood. 2017;130(Supplement 1):5459.
15. Costa L, Abbas J, Hogan K, et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant. 2012;47(11):1403-8. [DOI:10.1038/bmt.2012.60] [PMID]
16. Alva LC, Bacher U, Seipel K, et al. Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia. Transfusion. 2018;58(10):2365-73. [DOI:10.1111/trf.14895] [PMID]
17. Cluzeau T, Lambert J, Raus N, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transplant. 2016;51(5):687-91. [DOI:10.1038/bmt.2015.351] [PMID]
18. Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Exp Opin Pharmacother. 2014;15(1):23-36. [DOI:10.1517/14656566.2014.852537] [PMID]
19. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cell. 1996;14(1):106-16. [DOI:10.1002/stem.140106] [PMID]
20. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood.1995;86(10):3961-9. [DOI:10.1182/blood.V86.10.3961.bloodjournal86103961] [PMID]
21. Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91(9):3148-55. [DOI:10.1182/blood.V91.9.3148] [PMID]
22. Lutfi F, Skelton IV WP, Wang Y, et al. Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. Hematol Oncol Stem Cell Ther. 2020;13(1):23-31. [DOI:10.1016/j.hemonc.2019.08.003] [PMID]
23. Nagayama T, Ashizawa M, Ikeda T, et al. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma. Ann Hematol. 2020:1-9.
24. Yamaguchi J, Chinen Y, Takimoto-Shimomura T, et al. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leukemia Lymphoma. 2019;60(14):3434-41. [DOI:10.1080/10428194.2019.1636982] [PMID]
25. Grubovic RM, Georgievski B, Cevreska L, Genadieva-Stavric S, Grubovic MR. Analysis of factors that influence hematopoietic recovery in autologous transplanted patients with hematopoietic stem cells from peripheral blood. Open Access Maced J Med Sci. 2017;5(3):324. [DOI:10.3889/oamjms.2017.039] [PMID] [PMCID]
26. Lee K, Jung S, Kim S, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single‐centre experience. Vox Sang. 2014;107(4):407-15. [DOI:10.1111/vox.12183] [PMID]
27. Gambell P, Herbert K, Dickinson M, et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections. Biol Blood Marrow Transplant. 2012;18(5):763-72. [DOI:10.1016/j.bbmt.2011.10.002] [PMID]
28. Mohty M, Azar N, Chabannon C, et al. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. 2018;53(3):246-54. [DOI:10.1038/s41409-017-0033-0] [PMID]
29. Bao W, Liu R, Wang F, et al. Clinical analysis of autologous peripheral blood hematopoietic stem cell mobilization regimen in patients with malignant hematological diseases. Zhongguo shi yan xue ye xue za zhi. 2020;28(2):663-8.
30. Moreb JS, Byrne M, Shugarman I, et al. Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. J Clin Apher. 2018;33(1):29-37. [DOI:10.1002/jca.21556] [PMID]
31. Zheng G, He J, Cai Z, et al. A retrospective study of autologous stem cell mobilization by G CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett. 2020;19(1):1051-9. [DOI:10.3892/ol.2019.11177]
32. Yuan S, Wang S. How do we mobilize and collect autologous peripheral blood stem cells? Transfusion. 2017;57(1):13-23. [DOI:10.1111/trf.13868] [PMID]
33. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045-56. [DOI:10.1016/j.bbmt.2008.07.004] [PMID]
34. Weaver C, Birch R, Greco F, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;100(2):338-47. [DOI:10.1046/j.1365-2141.1998.00573.x] [PMID]
35. Baertsch MA, Kriegsmann K, Pavel P, et al. Platelet count before peripheral blood stem cell mobilization is associated with the need for plerixafor but not with the collection result. Transfus Med Hemother. 2018;45(1):24-31. [DOI:10.1159/000478911] [PMID] [PMCID]
36. Accorsi P, Dell'Isola M, Bonfini T, et al. Large volume leukapheresis with Amicus cell separator in peripheral blood stem cell autologous transplant. Transfus Apher Sci. 2001;24(1):79-83. [DOI:10.1016/S0955-3886(00)00130-2] [PMID]
37. Gašová Z, Marinov I, Vodvářková Š, Böhmová M, Bhuyian-Ludvíková Z. PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. Transfus Apher Sci. 2005;32(2):167-76. [DOI:10.1016/j.transci.2004.10.018] [PMID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
